Healio

Beneath the Surface: ‘Optimism is high’ for complex wound disease treatments

Please provide your email address to receive an email when new articles are posted on . There are few medications dermatologists can prescribe for pyoderma gangrenosum, a complex wound disease.

InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...
Nasdaq

InflaRx N.V. Showcases Promising Vilobelimab Data for Pyoderma Gangrenosum and Hidradenitis Suppurativa at AAD 2025 Annual Meeting

InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The ...
Seeking Alpha

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced an oral ...